Day Trader Alert: Gilead Sciences (GILD)

Health and Healthcare

Published: September 17, 2008 8:03 am

Last Updated: April 27, 2020 7:58 pm

Gilead Sciences Inc. (NASDAQ: GILD) is trading down this morning. Goldman Sachs maintained its buy rating on the stock, but took down its price target to $58 from $59. This report is after a negative complete response letter from FDA regarding aztreonam lysine for cystic fibrosis. Based upon the response, Goldman Sachs reduced the sales targets for 2008 by $20 million and 2009 by $110 million for the drug despite Gilead’s statement that it continues to work with the FDA on the issue.

The biotech giant is down roughly 4% at $47.70 on more than 36,000 shares. Its 52-week trading range is $37.17 to $57.63. While this is well above the 52-week lows, it is also the largest pullback from highs that we have seen over the last year.

Jon C. Ogg
September 17, 2008

Are You Ahead, or Behind on Retirement? (sponsor)

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention.

Finding a financial advisor who puts your interest first can be the difference between a rich retirement and barely getting by, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors that serve your area in minutes. Each advisor has been carefully vetted, and must act in your best interests. Start your search now.

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.